Completed PHASE3 INTERVENTIONAL 2-arm NCT01878526

Gastroesophageal Reflux Treatment in Scleroderma (GERD-SSc)

The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis

Sponsor: Khon Kaen University

Conditions Gastroesophageal Reflux Disease Scleroderma Systemic Sclerosis

Interventions Alginic acid Domperidone placebo (for domperidone) placebo (of alginic acid)

Updated 8 times since 2017 Last updated: Feb 3, 2017 Started: Jun 30, 2013 Primary completion: Aug 31, 2015 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Gastroesophageal Reflux Disease and Scleroderma, this trial is completed. The trial is conducted by Khon Kaen University and has accumulated 8 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
May 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jan 2017 — May 2017 [monthly]

Recruiting PHASE3

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Khon Kaen University

Data source: Khon Kaen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Khon Kaen, Thailand